Journal of Vascular and Interventional Radiology
Volume 20, Issue 12 , Pages 1617-1624 , December 2009

Delivery Site of Perivascular Endothelial Cell Matrices Determines Control of Stenosis in a Porcine Femoral Stent Model

  • Helen M. Nugent, PhD

      Affiliations

    • Department of Research and Development, Pervasis Therapeutics, One Kendall Square, Bldg 600, 1st Fl, Cambridge, MA 02139
    • Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts
    • Corresponding Author InformationAddress correspondence to H.M.N.
    • ,
  • Yin-Shan Ng, PhD

      Affiliations

    • Department of Research and Development, Pervasis Therapeutics, One Kendall Square, Bldg 600, 1st Fl, Cambridge, MA 02139
    • ,
  • Desmond White, BS

      Affiliations

    • Department of Research and Development, Pervasis Therapeutics, One Kendall Square, Bldg 600, 1st Fl, Cambridge, MA 02139
    • ,
  • Adam Groothius, MS

      Affiliations

    • Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts
    • Concord BioMedical Sciences and Emerging Technologies, Lexington, Massachusetts
    • ,
  • Glenn Kanner, BS

      Affiliations

    • Department of Research and Development, Pervasis Therapeutics, One Kendall Square, Bldg 600, 1st Fl, Cambridge, MA 02139
    • ,
  • Elazer R. Edelman, MD, PhD

      Affiliations

    • Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts
    • Cardiovascular Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts

References 

  1. Minar E, Pokrajac B, Maca T, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation. 2000;102:2694–2699
  2. Grimm J, Muller-Hulsbeck S, Jahnke T, Hilbert C, Brossmann J, Heller M. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol. 2001;12:935–942
  3. Cejna M, Thurnher S, Illiasch H, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol. 2001;12:23–31
  4. Tepe G. Drug-eluting stents for infrainguinal occlusive disease: progress and challenges. Semin Vasc Surg. 2006;19:102–108
  5. Machan L. Drug eluting stents in the infrainguinal circulation. Tech Vasc Interv Radiol. 2004;7:28–32
  6. Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701–710
  7. Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16:331–338
  8. Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation. 2002;106:1505–1509
  9. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. New Engl J Med. 2008;358:689–699
  10. Phillips-Hughes J, Kandarpa K. Restenosis: pathophysiology and preventive strategies. J Vasc Interv Radiol. 1996;7:321–333
  11. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol. 1999;10:499–506
  12. Nugent H, Sjin R, White D, et al. Adventitial endothelial implants reduce matrix metalloproteinase-2 expression and increase luminal diameter in porcine arteriovenous grafts. J Vasc Surg. 2007;46:548–556
  13. Nugent HM, Edelman ER. Endothelial implants provide long-term control of vascular repair in a porcine model of arterial injury. J Surg Res. 2001;99:228–234
  14. Nugent HM, Groothuis A, Seifert P, et al. Perivascular endothelial implants inhibit intimal hyperplasia in a model of arteriovenous fistulae: a safety and efficacy study in the pig. J Vasc Res. 2002;39:524–533
  15. Nugent HM, Rogers C, Edelman ER. Endothelial implants inhibit intimal hyperplasia after porcine angioplasty. Circ Res. 1999;84:384–391
  16. Russo RJ, Silva PD, Yeager M. Coronary artery overexpansion increases neointimal hyperplasia after stent placement in a porcine model. Heart. 2007;93:1609–1615
  17. Schwartz RS, Edelman ER, Carter A, et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation. 2002;106:1867–1873
  18. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999—2000. Circulation. 2004;110:738–743
  19. Schlager O, Dick P, Sabeti S, et al. Long-segment SFA stenting: the dark sides—in-stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther. 2005;12:676–684
  20. Bosiers M, Deloose K, Verbist J, Peeters P. Present and future of endovascular SFA treatment: stents, stent-grafts, drug coated balloons and drug coated stents. J Cardiovasc Surg. 2008;49:159–165
  21. Morrissey NJ. Biological treatment of vein grafts and stents in lower-extremity arterial reconstruction. Perspect Vascular Surg Endovascular Ther. 2007;19:293–297
  22. Nugent MA, Nugent HM, Iozzo RV, Sanchack K, Edelman ER. Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Proc Natl Acad Sci USA. 2000;97:6722–6727
  23. Lawson J, Conte M, Glickman M, et al. Safety of Vascugel treatment after the creation of arteriovenous access. Presented at the 42nd annual meeting of the American Society of Nephrology, Philadelphia, Pennsylvania, November 2008.
  24. Nathan A, Nugent MA, Edelman ER. Tissue engineered perivascular endothelial cell implants regulate vascular injury. Proc Natl Acad Sci USA. 1995;92:8130–8134
  25. Bobik A, Cambell JH. Vascular derived growth factors: cell biology, pathphysiology, and pharmacology. Pharmacol Rev. 1993;45:1–42
  26. Brovkovych V, Stolarczyk E, Oman J, Tomboulian P, Malinski T. Direct electrochemical measurement of nitric oxide in vascular endothelium. J Pharm Biomed Anal. 1999;19:135–143
  27. Lyon M, Rushton G, Gallagher JT. The interaction of the transforming growth factor-betas with heparin/heparan sulfate is isoform-specific. J Biol Chem. 1997;272:18000–18006
  28. Mulloy B. The specificity of interactions between proteins and sulfated polysaccharides. An Acad Bras Cienc. 2005;77:651–664
  29. Taipale J, Saharinen J, Hedman K, Keski-Oja J. Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrils. J Histochem Cytochem. 1996;44:875–889
  30. Passerieux E, Rossignol R, Chopard A, et al. Structural organization of the perimysium in bovine skeletal muscle: junctional plates and associated intracellular subdomains. J Struct Biol. 2006;154:206–216
  31. Kutschka I, Chen IY, Kofidis T, et al. Collagen matrices enhance survival of transplanted cardiomyoblasts and contribute to functional improvement of ischemic rat hearts. Circulation. 2006;114(1 Suppl):I167–I173

 H.M.N., Y.S.N., G.K., and D.W. are employees of and have shares in Pervasis Therapeutics. E.R.E. is on the board of directors and has shares in Pervasis Therapeutics. E.R.E. was supported by grants from USA National Institutes of Health (GM 49039). Research described in this article was supported by Pervasis Therapeutics. The other author has not identified a conflict of interest.

PII: S1051-0443(09)00882-3

doi: 10.1016/j.jvir.2009.08.020

Journal of Vascular and Interventional Radiology
Volume 20, Issue 12 , Pages 1617-1624 , December 2009

Article Tools

* Image Usage & Resolution